The ABCC9 antibody targets the protein product of the ATP-binding cassette subfamily C member 9 (ABCC9) gene, which encodes sulfonylurea receptor 2 (SUR2), a regulatory subunit of ATP-sensitive potassium (KATP) channels. KATP channels, composed of SUR subunits and pore-forming Kir6.x subunits (Kir6.1 or Kir6.2), play critical roles in coupling cellular metabolic status to electrical activity. SUR2 exists in two splice variants, SUR2A (predominantly in cardiac and skeletal muscle) and SUR2B (in smooth muscle and brain), differing in the terminal exon. These channels regulate vascular tone, insulin secretion, and cardioprotection during ischemia. ABCC9 mutations are linked to human diseases, including dilated cardiomyopathy, Cantú syndrome, and epilepsy. Antibodies against ABCC9/SUR2 are essential tools for studying protein expression, localization, and functional roles in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate tissue-specific distribution or altered expression in disease models. Research applications span cardiovascular biology, neurobiology, and metabolic disorders, with therapeutic implications for conditions like hypertension, diabetes, and heart failure. Validation of ABCC9 antibodies requires specificity checks due to structural similarities among ABC transporter family members.